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Abstract
Background: In spite of progress in diagnostics and treatment of Hepatocellular Carcinoma (HCC), its prognosis
remains poor, and improved treatment strategies for HCC require detailed understanding of the underlying
mechanism. In this investigation we studied the role of Up-frameshift 1 (UPF1) in the tumorigenesis of HCC.
Methods: We determined the expression level of UPF1 in HCC tissues with quantitative real-time PCR and
western blotting and then studied its clinical significance. Sodium bisulfite sequencing was used to investigate the
regulation of UPF1. We explored the biological significance of UPF1 with gain-and-loss-of-function analyses both in
vitro and in vivo. The relationship between UPF1 and SMAD7 was also investigated by western blotting and
immunofluorescence.
Results: A great downregulation of UPF1 due to promoter hypermethylation was observed in tumor tissues
compared to their adjacent normal tissues. Meanwhile, patients with low UPF1 expression have significantly
poorer prognosis than those with high expression. Functionally, UPF1 regulated HCC tumorigenesis both in vitro and
in vivo. Moreover, the decreased UPF1 level in HCC reduces NMD efficiency and leads to up-regulation of Smad7, then
affects the TGF-β pathway.
Conclusion: Our findings revealed that UPF1 is a potential tumor suppressive gene and may be a potential therapeutic
target for HCC.
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Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related deaths worldwide [1]. Although
recent advances in cancer treatment with respect to
surgery, chemotherapy and biologics, majority of HCC
remains incurable once it has become metastatic and
has a poor prognosis [2]. The details of the molecular
mechanisms underlying HCC carcinogenesis remain to
be elucidated. Hepatocarcinogenesis has often been de-
scribed as a multistep process involving a number of
genetic alterations eventually leading to the malignant
transformation of the hepatocytes [3].
Tumor suppressor genes protect normal cells from
progressing to cancer in general [4]. However, these
genes in cancer cells often suffer genetic mutations and
aberrant epigenetic modifications [5, 6]. The mutations
generate mRNA harboring premature termination co-
dons (PTCs) that are targets of nonsense-mediated
mRNA decay (NMD) pathway [7]. Hence NMD regula-
tion and aberrant epigenetic modifications contribute to
oncogenesis [8, 9] NMD is an mRNA surveillance path-
way that eliminates aberrant mRNA transcript contain-
ing PTCs, and prevents the synthesis of potentially toxic
truncated proteins [10]. Recent studies have shown that
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NMD is not only a quality control pathway, but also a
regulatory pathway that controls normal gene expres-
sion. Gene expression profiling studies have shown that
either loss or depletion of NMD factors in species scal-
ing the phylogenetic scale leads to the dysregulation of
3 %–15 % of normal transcripts [11]. The core of the
human NMD machinery is composed of seven polypep-
tides called Up-frameshift 1 (UPF1), UPF2, UPF3,
SMG1, SMG5, SMG6, and SMG7 [12]. Human UPF1
also mediates two RNA decay processes, which are in-
dependent of canonical NMD as they do not require
UPF2: first, it targets those mRNA molecules that are
bound to the RNA binding protein Staufen1 for degrad-
ation [13]; second, together with Stem-Loop Binding
Protein (SLBP), it promotes degradation of replication-
dependent histone mRNAs at the end of S phase and
when DNA replication is inhibited [14].
Recent studies have demonstrated that UPF1 is not only
a key player in RNA degradation pathways, but that it is
also essential for accomplishing DNA replication during S
phase of the cell cycle [15]. UPF1 was required for S Phase
progression and genome stability. UPF1 also plays a key
role in the process of cell proliferation and differentiation
by promoting the proliferative, undifferentiated cell state.
UPF1 acts, in part, by destabilizing the NMD substrate en-
coding the TGFβ inhibitor, Smad7, and stimulating TGF
signaling [16]. UPF1 also promotes the decay of mRNAs
encoding many other proteins that oppose the prolifera-
tive, undifferentiated cell state. Liu and his colleagues
found that UPF1 was down-regulated in pancreatic
adenosquamous carcinoma (ASC) and the UPF1 gene
is commonly mutated in pancreatic adenosquamous car-
cinoma [17]. The discovery of mutations in the UPF1 gene
in ASC tumors represents the first known example of gen-
etic alterations in a NMD gene in human tumors. While
no studies have assessed UPF1 exact activity in human
HCC, which prompted our interest in investigating its bio-
logical roles of UPF1 in hepatocarcinogenesis.
In the present study, we demonstrated that UPF1
was significantly down-regulated in HCC tissues as
compared with adjacent non-tumor tissues, and this
down-regulation of UPF1 was associated with de-
creased survival of HCC patients. Furthermore, we
found that UPF1 was regulated by CpG island methy-
lation of the putative promoter region. Functional
analyses indicated UPF1 inhibited both cell growth
and tumorigenicity of HCC cells, possible by targeting
Smad7 and then effects on TGF-β pathways.
Methods
Clinical specimens and cell lines
HCC specimens and the corresponding adjacent tissues
were collected from Zhongnan Hospital of Wuhan
University after obtaining informed consent. The diagnosis
of HCC was histopathologically confirmed. The protocols
used in the study were approved by the Hospital’s Protec-
tion of Human Subjects Committee. Overall survival (OS)
was defined as the interval between resection and death or
the last follow-up visit. Recurrence free survival (RFS) was
defined as the interval between treatment and the first
diagnosis of metastasis or recurrence. L02, Huh7, Hep3B,
HepG2, SMMC-7721 and HCCLM9 included in this study
were purchased from the Cell Bank of Type Culture
Collection (CBTCC, Chinese Academy of Sciences,
Shanghai, China) and cultured in minimum essential
medium (Gibco, Carlsbad, CA, USA) with 10 % fetal
bovine serum (Gibco).
Quantitative real-time PCR
Total RNA was extracted from tissues and cells using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The re-
verse transcription of mRNA was performed using Oligo-
dT primer. Quantitative real-time PCR was performed
using a standard protocol from the SYBR Green PCR kit
(Toyobo, Osaka, Japan) on an iQ5 quantitative PCR Sys-
tem (Bio-Rad, USA). β-actin was used as an internal con-
trol, and 2−ΔΔCT values were normalized to β-actin levels.
Each sample was analyzed in triplicate. Primers used in
this study are presented in Table 1.
Plasmid constructions and transfection assay
UPF1 (Gene-bank: NM_001297549.1) was cloned into
pcDNA3.1 vector (Life Technology). UPF1-siRNAs were
Table 1 Primer sequence and target sequence used in this
study
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designed and synthesized by Viewsolid Biotech (Beijing,
China). The sequence of siRNAs are presented in Table 1.
The expression of UPF1 was confirmed by RT-qPCR
and western blotting. Transfection was carried out using
FuGene HD transfection reagent (Roche, Indianapolis,
IN) according to the manufacturer’s protocol.
Immunohistochemistry (IHC) and Immunofluorescence (IF)
For IHC, paraffin sections were cut to a thickness of
4 μm, the slides were deparaffinized in xylene and rehy-
drated with ethanol, and the endogenous peroxidase was
inactivated with 0.3 % hydrogen peroxide. All of the
steps were performed using an UltraSensitiveTM S-P kit
(Maixinbio, China) according to the manufacturer’s
protocol. The total immunostaining score was calculated
as the sum of the positive percentage and the staining
intensity of the stained cells, which ranged from 0 to 6.
The percent positivity was scored as “0” (0–25 %), “1”
(26–50 %), “2” (51–75 %), and “3” (≥75 %). The staining
intensity was scored as “0” (no staining), “1” (weakly
stained), “2” (moderately stained), and “3” (strongly
stained). A negative expression of protein was defined as
a total score ≤ 3, and a positive expression was defined
as a total score ≥ 4. For immunofluorescence, cells were
fixed in 4 % paraformaldehyde, permeabilized using
0.5 % Triton X-100 and incubated with primary antibody
and secondary antibodies used according to the manu-
facturer’s protocol. The coverslips were counterstained
with DAPI and imaged with a confocal laser-scanning
microscope (Olympus FV1000, Tokyo, Japan). Anti-
bodies used in this study were presented in Table 2.
Flow cytometry analysis
Cells transiently transfected with siRNA or vector
were harvested 48 h after transfection. Following the
double staining with Annexin V FITC and Propidium
Iodide (PI), the cells were analyzed by flow cytometry
(FACScan®; BD Biosciences, San Jose, CA) equipped
with CellQuest software (BD Biosciences). For the cell
cycle analysis, the cells were stained with PI using the
CycleTESTTM PLUS DNA reagent kit (BD Biosciences)
according to the manufacturer’s instruction.
Western blotting
Tissular and cellular proteins from each sample were
electrophoresed by SDS-polyacrylamide gel electrophor-
esis (4 % stacking and 10 % separating gels), then
transferred onto polyvinylidene fluoride PVDF membranes
(Millipore, USA), then incubated with primary antibodies
overnight at 4 °C. After the incubation with secondary
antibodies, the PVDF membranes were subsequently sub-
jected to immunoblotting analysis using the ECL im-
munoblotting kit (Beyotime Institute of Biotechnology,
China) according to the manufacturer’s protocol. Anti-
bodies information used in this study was listed in Table 2.
Transwell and wound healing assay
The invasion of cells was assessed using Matrigel-coated
chambers with 8 μm pores (BD Biosciences, Franklin
Lakes, NY, USA). Briefly, hepatoma cells (1 × 105) were
seeded in serum-free medium and were allowed to
translocate toward complete media supplemented with
10 % fetal bovine serum after depleted of UPF1. The
cells that had invaded through the membrane to the
lower surface were fixed, stained and counted after 24 h.
HCC cells (1 × 106 cells/well) were treated with the indi-
cated reagents, and wounds were made using a 100 μl
plastic pipette tip. The size of the wound was measured
after 24 h of wound formation and photographed.
CCK-8 cell proliferation assay
Cell proliferation assay was performed by using Cell
Counting Kit-8 (Dojindo, Japan). Briefly, cells were plated
in 96-well plates in triplicate at aproximately 3–5 × 104
cells per well and cultured in the growth medium. Cells
were then treated with the indicated reagent and the num-
bers of cells per well were measured by the absorbance
(450 nm) at the indicated time points.
Sodium bisulfite sequencing
MethPrimer (http://www.urogene.org/cgi-bin/methpri-
mer/methprimer.cgi) was used to analyze the CpG islands.
Genomic DNA was extracted using DNeasy Tissue Kit
(QIAGEN, Valencia, CA). Genomic DNA was treated with
sodium bisulfite using the CpGenome DNA Modification
Kit (Serologicals Corp, Norcross, GA) according to the
manufacturer’s protocol. PCR products were subcloned,
and ten constructs representing each region from each
sample were randomly selected for sequence analysis.
DNA methylation data were analyzed by using BiQ
Analyzer (http://biq-analyzer.bioinf.mpi-inf.mpg.de/.).
Table 2 Antibody information used in this study
Antibody WB IHC IF Specificity Company
GAPDH(KM9002) 1:5000 Mouse monoclonal Sungene
UPF1(#12040) 1:1000 1:100 1:400 Rabbit polyclona Cell Signaling Technology
SMAD7(sc-101152) 1:500 1:200 1:100 Mouse monoclonal Santa Cruz Biotechnology
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Tumor formation assay in a nude mouse model
HCCLM9 cells stably transfected with pcDNA3.1-UPF1
or empty vector were suspended at 1 × 107 cells/ml. A
total of 100 μl of suspended cells were subcutaneously
injected into the male athymic BALB/c nude mice
(5 weeks old). Tumor volumes and weights were mea-
sured beginning from day 7 after the tumor cell injection.
Tail vein injections into athymic mice
HCCLM9 cells stably transfected with pcDNA3.1-UPF1
or the empty vector were suspended at 2 × 107 cells/ml.
Suspended cells (100 μl) were injected into the tail veins
of 10 mice (5 weeks old), which were sacrificed 7 weeks
after injection. The lungs were removed and visible
tumors on the lung surface were counted and used for
further analysis.
Statistical analysis
Data are presented as the means ± standard deviation
from at least three independent experiments. Stu-
dent’s t-test, χ2 test or Fisher’s exact tests were used
for comparisons between groups with SPSS 22.0 soft-
ware (IBM, Chicago, IL, USA). The Kaplan-Meier test
was used to estimate OS and RFS. A value of p < 0.05
was considered significant.
Results
UPF1 was strongly downregulated in HCC and associated
with HCC progression
The expression level of UPF1 was first examined by IHC
in 50 HCC patients. UPF1 was downregulated in HCC
tissues compared with adjacent non-tumor tissues
(Fig. 1a). Western blotting further confirmed the lower
expression of UPF1 in HCC tissues (Fig. 1b). We next
examined the expression of UPF1 by quantitative RT-
PCR in 50 HCC patients. Figure 1c and d show sig-
nificantly lower UPF1 expression in HCC tissues. In
vitro, UPF1 expression is decreased in hepatoma cells
compared with normal liver cells (Fig. 1e). Aberrant
expression of UPF1 was closely correlated with
Edmondson-Steiner grade (P = 0.015), Barcelona Clinic
Liver Cancer stage (BCLC; P = 0.020) and portal vein
tumor thrombus (PVTT; P = 0.031) (Table 3). Further-
more, Kaplan-Meier and log-rank test analyses sug-
gested that HCC patients with low UPF1 expression
have shorter overall survival (OS) and higher recur-
rence rates than those with high expression of UPF1
(Fig. 2a and b).
UPF1 suppressed HCC tumorigenesis in vitro and in vivo
The significant downregulation of UPF1 expression in
HCC tissues suggested possible biological significance in
tumorigenesis. We evaluated the effects of UPF1 on cell
apoptosis and cell cycle progression in HCCLM9 and
Huh7 cells transfected with either pcDNA3.1-UPF1 or
UPF1-siRNA. Measured using RT-qPCR, the expression
of UPF1 was 6.3-fold (HCCLM9) and 5.7-fold (Huh7)
increased in cells transfected with pcDNA3.1-UPF1, but
20-fold (HCCLM9) and 5-fold (Huh7) deceased in cells
transfected with 20nM UPF1-siRNA (Fig. 3a). Cells
treated with empty vector or scrambled siRNA showed
no significant differences in UPF1 expression.
Fluorescence-activated cell sorting (FACS) analysis
showed significant increases in apoptotic cells when UPF1
was overexpressed (Fig. 3b). Cell cycle analysis showed
that in UPF1-siRNA transfected cells, the percentage of
cells in the S phase was more than that of scramble siRNA
transfected cells. (Fig. 3c). Similar results were observed in
Huh7 cells. Together, these results suggest that UPF1
could suppress HCC cell proliferation by inducing cell
cycle arrest.
To further examine the effects of UPF1 on HCC
tumorigenesis, the biological consequences of UPF1 in
regulating cancer cell invasion and migration were ex-
amined using cell biology assays. As shown in Fig. 3d,
functionally, knockdown UPF1 increased the cell inva-
sion and migration of HCC cells. While, overexpression
of cellular UPF1 significantly decreased the cell invasion,
migration and proliferation of HCC cells (Fig. 3e and f).
To investigate the roles of UPF1 in tumorigenesis in
vivo, HCCLM9 cells which were stably transfected with
pcDNA3.1-UPF1 and control cells were inoculated into
the oxter of male nude mice. We found UPF1 overex-
pressed dramatically inhibited tumor growth (Fig. 4a-d).
Moreover, UPF1 overexpressed dramatically reduced
positivity for Ki-67 (Fig. 4e). We next evaluated the
in vivo effects of UPF1 on metastasis using a lung
metastasis model. The numbers of pulmonary meta-
static nodules in the lung were clearly greater in the
control group compared with the UPF1 overexpressed
group. In addition, the HE staining of lung section
showed that UPF1 overexpressed reduced the number
of visible lung metastases (Fig. 4f ).
CpG hypermethylation downregulated UPF1 expression in
HCC
Study had shown hypermethylation of tumor suppressor
genes contribute to tumorigenesis [18]. To investigate
the underlying mechanism responsible for downregula-
tion of UPF1 in HCC, we tested whether hypermethyla-
tion are involved in the progression. Using MethPrimer
software we found several CpG islands were contained
in promoter region of UPF1. We speculated hyperme-
thylation may take a key role in the regulation of UPF1.
First, 5-Aza-2′-deoxycytidine-the methylation inhibitor
was used to demethylate genomic DNA. As shown in
Fig. 5a, the protein and mRNA expression level was
gradually increased in HCCLM9 and Huh7 cells
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following treatment with increased concentrations of
5-Aza-2′-deoxycytidine. To explore the relationship
between promoter methylation and UPF1 gene down-
regulation, we utilized CpG island prediction software
to analyze the promoter region of UPF1. As shown in
Fig. 5b fragment (18831624 ~ 18832749 in chromo-
some 19, NC_000019.10) was rich in CpG dinu-
cleotides and predicted as a putative promoter region
by the Meth-Primer software. To examine the
methylation pattern, the fragment containing a total
of 26 CpG dinucleotides, was amplified from genomic
DNA isolated from HCC and non-tumor tissues
treated with either sodium bisulfite or vehicle.
Figure 5c shows a representative methylation pattern
of the 26 CpGs putative promoter region. In non-
tumor tissues, the majority of CpGs were unmethy-
lated, whereas in the tumor tissues, most of the CpGs
were methylated. The methylation status of each CpG
Fig. 1 UPF1 was downregulated in human HCC tissues and HCC cells. a Representative IHC images showing the downregulation of UPF1 in HCC
tissue (up) and the normal expression of UPF1 in HCC adjacent non-tumor tissue (down). (Scale bars = 50 μm) (b) The UPF1 protein expression
levels in HCC tissues and paired non-tumor tissues were examined using Western blotting. c The expression of mRNA level of UPF1 was detected
in 50 HCC patients by RT-qPCR. Data was presented as fold change of HCC tissues relative to adjacent normal regions. *p < 0.05; **p < 0.01. d Relative
UPF1 expression level in HCC tissues and adjacent normal regions. *p < 0.01. e The relative mRNA level of UPF1 in HCC cell lines (HepG2,
Huh7, SMMC-7721, HCCLM9, and Hep3B) and human normal liver cell (L02); for all quantitative results, the data are presented as the
mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01
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was quantified using the percentage of methylated
CpGs among all PCR products analyzed. 53.85 % (14/
26) CpGs were hypermethylated in tumors compared to
15.38 % (4/26) in normal tissues (Fig. 5d).
Smad7 was strongly up-regulated in HCC
The expression level of Smad7 was first examined by
IHC in 50 HCC patients. Smad7 was up-regulated in
HCC tissues compared with adjacent non-tumor tissues
(Fig. 6a). We next examined the expression of UPF1 by
quantitative RT-qPCR in 50 HCC patients. Figure 6b
showed significantly higher Smad7 expression in HCC
tissues. Western blotting further confirmed the higher
expression of Smad7 in HCC tissues (Fig. 6c).
UPF1 suppressed HCC tumorigenesis by targeting Smad7
and affected TGF-β pathway
Study had shown that UPF1 could promote TGF-β sig-
naling and inhibits neural differentiation by targeting
Smad7 mRNA [16]. Whether UPF1 affects Smad7 in
human tumorigenesis? Up to now, it has not been re-
ported, which prompted our interest in investigating the
relationship between UPF1 and Smad7 in HCC. First, we
analyzed the relationship between their expression levels
in HCC tissues. As shown in Fig. 7a and b, the protein
expression level of UPF1 and Smad7 in the paired tissues
was negative associated and an inverse correlation was
found between UPF1 and Smad7 expression levels in 50
pairs of HCC tissues by RT-qPCR. Western blotting and
Fig. 2 Low UPF1 expression predicts poor prognosis in patients with
HCC. a Kaplan-Meier curves displaying overall survival of patients
with high UPF1 expression vs low UPF1 expression (p < 0.01, Log-rank
Test). b Kaplan-Meier curves displaying recurrence-free survival of
patients with high UPF1 expression vs low UPF1 expression
(p < 0.05, Log-rank Test). The median mRNA expression level was
used as the cutoff. Patients with UPF1 mRNA expression values
below the 50th percentile were classified as having lower UPF1
levels. Patients with UPF1 expression values above the 50th
percentile were classified as having higher UPF1 levels
Table 3 Relationship between UPF1 expression and
clinicopathologic parameters of HCC patients
Characteristics Number
of cases
UPF1 expression P value
Low(n = 25) High(n = 25)
Age(years) 0.152
≥ 65 29 17 12
< 65 21 8 13
Gender 0.157
Male 40 18 22
Female 10 7 3
Tumor size 0.364
≥ 5 cm 32 19 13
< 5 cm 18 6 12
Edmondson-Steiner 0.015*
I-II 34 21 13
III-IV 16 4 12
HBV infection 0.088
Postive 39 17 22
Negtive 11 8 3
BCLC stage 0.020*
A 42 24 18
B + C 8 1 7
Liver cirrhosis 0.225
Yes 34 15 19
No 16 10 6
Serum AFP(μg/L) 0.771
≥ 400 31 16 15
< 400 19 9 10
Tumor number 0.747
Singular 37 18 19
Multifocal 13 7 6
PVTT 0.031*
Yes 15 4 11
No 35 21 14
Barcelona Clinic Liver Cancer stage: BCLC
Portal vein tumor thrombus: PVTT
*p < 0.05
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immunofluorescence confirmed that Smad7 expression
level was up-regulated when UPF1 was silenced in
HCC cells (Fig. 7c and e). While the Smad7 expres-
sion level was down-regulated when UPF1 was over-
expressed in HCC cells (Fig. 7d). Previous studies had
demonstrated the key role of Smad7 in the TGF-β
pathway. As shown in our study, UPF1 could affect
the expression of Smad7 in HCC. Therefore, we spec-
ulated that UPF1 could affect the TGF-β pathway. To
verify these findings, the key molecules in the TGF-β
pathway (Smad2 and Smad3) were detected by west-
ern blotting. As shown in Fig. 7f, UPF1 overexpres-
sion significantly increased phosphorylation of Smad2/
3, whereas total Smad2/3 expression level was not
significantly altered. These results were reversed
under conditions of UPF1 knockdown. These results
indicate that the TGF-β pathways may be involved in
UPF1 suppression of tumorigenesis.
Discussion
In this study, we reported the correlation between UPF1
silencing and HCC. Immunohistochemical analysis,
western blotting and RT-qPCR experiments showed that
the down-regulation of UPF1 was associated with malig-
nant progression of HCC. Epigenetic silencing of UPF1
gene was observed in low UPF1-expressing HCC cell
lines. Therefore, we deducted that UPF1 silencing may
be required for tumorigenesis and has a potential to be
developed as a biomarker for malignant phenotype of
HCC, which possesses considerable value in prognosis
prediction, progression monitoring and treatment evalu-
ating. For future application, it is critical to design rea-
sonable clinical trial for evaluation of this biomarker.
Not only overall survival and recurrence-free survival
should be evaluated in randomized, controlled trials,
some key factors with regard to HCC, such as HBV in-
fection information, will be considered.
Fig. 3 The functional analysis of UPF1 in HCC cells. a UPF1 mRNA level was detected in HCCLM9 and Huh7 cells after treatment with UPF1-siRNA
and pCDNA3.1-UPF1 by RT-qPCR. *p < 0.05; **p < 0.01 (b) Flow cytometry was applied to examine the apoptosis of HCCLM9 and Huh7
cells after treatment with pCDNA3.1-UPF1 and stained with apoptosis markers (FITC-Annexin V and PI). In the apoptosis map, FITC-Annexin V+/PI+
indicates late apoptosis, FITC-Annexin V+/PI− indicates early apoptosis, and FITC-Annexin V−/PI− indicates normal live cells. *p < 0.05 (c) Flow cytometry
analysis showing significant decreases of cells in the S- phase, when UPF1 was silenced in HCCLM9 and Huh7 cells. d The ability of cancer cell invasion
and migration was measured by using transwell and wound-healing assays when UPF1 was silenced in HCCLM9 and Huh7 cells (Transwell [original
magnification, ×200]; wound-healing assays [original magnification, ×100]). e The ability of cancer cell invasion and migration was measured by
using transwell and wound-healing assays when UPF1 was overexpressed in HCCLM9 and Huh7 cells (Transwell [original magnification, ×200];
wound-healing assays [original magnification, ×100]). f CCK-8 and assay showing that overexpression of UPF1 inhibited the proliferation of HCCLM9
and Huh7 cells. *p < 0.05
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Generally speaking, hypermethylation of tumor suppres-
sor genes and demethylation of oncogenes contribute to
tumorigenesis [18, 19]. Cancer-linked hypermethylation
and hypomethylation of gene promoter is often associated
with cell proliferation and differentiation [20]. In this
study, we found UPF1 is a potential tumor suppres-
sor, which negatively regulates proliferation of cancer
cells, we also observed that UPF1 is down-regulated
in HCC tissues. In HCC tissues and cell lines, the
methylation states of the CpGs in UPF1 promoter re-
gion were found to be hypermethylated. Moreover,
UPF1 gene was also re-expressed following treatment
with 5-Ad, a potent demethylating agent, suggesting
that status of DNA demethylation was important for
the active expression of UPF1.
NMD is an evolutionally conserved mRNA quality-
control mechanism that selectively degrades aberrant
mRNA containing premature termination codons in
Fig. 4 Downregulation of UPF1 promoted tumor growth and metastasis in vivo. a Representative images of tumors formed in nude mice
injected subcutaneously with HCCLM9 control cells (Control) and pcDNA3.1-UPF1 stable clones (UPF1). b Representative images of tumors
removal from the nude mice. c, d Effect of UPF1 on HCC growth was described by the tumor growth curve and tumor weight in the two
groups. Data are shown as the mean ± s.d. *p < 0.05; **p < 0.01. e Immunohistochemical staining for Ki-67 in tumor xenografts of nude mice
formed by the two groups. (Scale bars = 30 μm). The proportion of Ki-67 positive cells was also shown. **p < 0.01. f Representative images of HE
staining of metastatic nodules in the lungs of nude mice. The metastatic nodules are indicated by yellow arrows. (Scale bars = 50 μm). *p < 0.05
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order to prevent the accumulation of truncated proteins
[21], which are often non-functional or potentially dele-
terious in the cells. Three conserved proteins UPF1,
UPF2, and UPF3 make up the key NMD machinery with
UPF1 as the important member in this protein set
[22–24] UPF1 acts in concert with the peptide release
factors eRF1/eRF3 to recognize aberrant translation
termination events and, together with UPF2 and
UPF3, triggers degradation of mRNA in a subsequent
step [25, 26]. In addition to its role in NMD, UPF1
also regulates mRNAs in a NMD-independent man-
ner. For example, UPF1 is recruited by the RNA-
binding protein Staufen to the downstream of a stop
cordon to degrade some mRNAs in a Staufen-
mediated decay [13]. Human UPF1 has been shown
to regulate the degradation of histone mRNAs in
mammalian cells [27]. Moreover, UPF1 is involved in
nonsense-mediated altered splicing [28]. Although
Fig. 5 CpG island hypermethylation was associated with UPF1 downregulation. a Demethylation following treatment with 5-Aza-2′ -deoxycytidine
induced UPF1 up-regulation in HCCLM9 and Huh7 cells, the protein and mRNA expression level of UPF1 was checked by western blotting and
RT-qPCR respectively. **p < 0.01. (b) The CpG island enriched sites in the upstream region of UPF1 were analyzed using CpG islandsearcher. c The
CpG island enriched sites in the upstream region of UPF1 were analyzed using Meth-Primer (d) Bisulfite sequencing of the putative promoter region. Each
line represents one PCR product, and ten PCR products are shown for each sample. ●, methylated CpGs; ○, unmethylated CpGs. e The methylation
status of each CpG in this region was quantified using the percentage of methylated CpGs among all PCR products. *p < 0.05, **p < 0.01
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NMD pathway has been extensively studied, the regu-
latory mechanism of NMD in cancer is still not well
understood. The first report about the relationship
between UPF1 and human tumor is pancreatic ade-
nosquamous carcinoma. UPF1 was found down-
regulated in pancreatic adenosquamous carcinoma
[17], here, in our study, we found UPF1 was also down-
regulated in HCC. In addition, as a key molecule in the
TGF-β pathway, Smad7 was an inhibitory SMAD protein.
We found UPF1 could suppress the Smad7 level in HCC
and then affected the TGF-β pathway.
Conclusion
In conclusion, the current study revealed that UPF1
was down-regulated in HCC cells and tissues. Fur-
thermore, UPF1 suppressed tumorigenesis of HCC.
Finally, the reduced UPF1 expression, due to pro-
moter hypermethylation, attenuated NMD, leaded to
Fig. 6 Smad7 was overexpressed in HCC tissue. a Representative IHC images showing the upregulation of Smad7 in HCC tissue (up) and the normal
expression of Smad7 in HCC adjacent non-tumor tissue (down). (Scale bars = 30 μm). b The expression of mRNA level of Smad7 was detected in 50
HCC patients by RT-qPCR. **p < 0.01. c The Smad7 protein expression levels in HCC tissues and paired non-tumor tissues were examined using western
blotting. *p < 0.05; **p < 0.01
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the dysregulation of Smad7, which indicated aberrant
mRNA surveillance mechanism in HCC. All the re-
sults indicated that UPF1 played an important role
during HCC carcinogenesis and may serve as a puta-
tive target for HCC diagnosis and therapy.
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